Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

By D. Cunningham, I. Láng, E. Marcuello, V. Lorusso, J. Ocvirk, D. Shin, D. Jonker, S. Osborne, N. Andre, D. Waterkamp and 1 more. The Lancet Oncology, 2013

613 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/7da083ce90bf4df8eecd9d8feffbdd53d2c67d52

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. N. Vasudev
2. Andrew R Reynolds
3. Rakesh K. Jain

Citations in the corpus

• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Metastatic 1st line FOLFIRI ± bevacizumab AVF2107 [19] Improvement in OS and PFS FOLFOX or XELOX ± bevacizumab NO16966 [21] Improvement in OS and PFS Capecitabine ± bevacizumab AVEX [22] Improvement in PFS, OS NA FOLFIRI ± sunitinib SUN1122 [28] No improvement in PFS FOLFOX ± vatalanib CONFIRM 1 [29”
• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Bevacizumab has been shown to increase the survival, PFS and RR in first-line treatment in combination with 5-FU/LV/ irinotecan and in combination with 5-FU/LV or capecitabine alone [I, B] [11, 15–17].”